The latest happenings in the industry, all in one place.
Ergomed plc announced the appointment of Lewis Cameron as Chief Operating Officer and to the Board.
CTI Clinical Trial and Consulting Services has announced the additions of Savannah Doliboa and Nick Finan to the Business Development department and Rochelle Maher to the Regulatory & Scientific Affairs department. They also announced the promotions of Ana Patacão to Executive Director, Real World Evidence & Late Phase, and Brian Johnston to Senior Director, Clinical Project Management.
LaRee Tracy
PHASTAR announced the hiring of LaRee Tracy, PhD, as Director of Biostatistics.
Spaulding Clinical Research has announced that it has named Cassandra Erato Chief Executive Officer.
Syntactx announced that Dorothy Abel has joined the company as Vice President, Regulatory Strategy.
Continuum Clinical has announced Paul Ivsin as the new Vice President of Data and Analytics.
Clinerion and Datametrix partner to deliver Real World Evidence insights from Real World Data from Clinerion’s global hospital network.
In 2019, AG Mednet realized more than 35 percent growth both in revenue and new product sales, and nearly 40 percent growth in average deal-value.
Nebraska Innovation Campus has announced Celerion will move into a space on the campus.
Veeva Systems announced that an increasing number of life sciences companies are adopting applications in the Veeva Vault RIM Suite to streamline regulatory information management.
PHASTAR announced that the company has chosen San Diego as the site for its new U.S. West Coast office.
Novotech has won the Australian-Korean Business Awards 2020 - Award for Excellence, in the category Biotech and Health.
Advanced Clinical has been recognized by ClearlyRated, earning the Best of Staffing Client and Talent Awards for the fifth consecutive year.
Phase III Trial of Keytruda Plus Lynparza for NSCLC Stopped Due to Futility
December 7th 2023KEYLYNK-008 trial finds that Keytruda in combination with chemotherapy followed by Keytruda plus Lynparza did not produce an improved overall survival benefit in patients with metastatic squamous non-small cell lung cancer.
Key Phase III Trial Results Lead to FDA Approval of Fabhalta for Paroxysmal Nocturnal Hemoglobinuria
December 6th 2023Clinical trials demonstrated superiority of Fabhalta to anti-C5s in hemoglobin improvement in the absence of transfusions and transfusion avoidance rate, showing clinically meaningful hemoglobin-level increases without the need for blood transfusions in patients with paroxysmal nocturnal hemoglobinuria.